Prescription drug · NDA
Talzenna (talazoparib) NDC 0069-0655
Talazoparib tosylate .75 mg/1 · Capsule, Liquid filled · Oral · Pfizer Laboratories Div Pfizer Inc
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0069-0655-30 | 00069065530 | 30 CAPSULE, LIQUID FILLED in 1 BOTTLE (0069-0655-30)Marketed from Apr 17, 2024 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Talzenna
- Generic name (nonproprietary)
- talazoparib
- Active ingredients
- Talazoparib tosylate — .75 mg/1
- Dosage form
- Capsule, Liquid filled
- Route
- Oral
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 217439
- Marketing start
- Listing expires
- Other FDA classes
- Poly(ADP-Ribose) Polymerase Inhibitors (Mechanism)
- Identifiers
- Product ID 0069-0655_79f127ad-8339-4132-a957-efae653394fcSPL ID 79f127ad-8339-4132-a957-efae653394fcSPL set ID c6fd147f-a77e-4a0b-9280-e82ecc41b4beRxCUI 2099946, 2099952, 2099954, 2099956, 2591510, 2591512, 2591520, 2591521, 2639960, 2639962, 2639964, 2639966UNII 02WK9U5NZCUPC 0300690353302, 0300690252308, 0300690757308, 0300690454306, 0300690546308
- Pharmacologic class
- Poly(ADP-Ribose) Polymerase Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400069065530followed by a unit qualifier and the quantityPackage 00069-0655-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for: Breast Cancer • As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA m) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-approved companion diagnostic for TALZENNA. ( 1.1 ) HRR Gene-mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) • In combination with enzalutamide for the treatment of adult patients with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC). ( 1.2 ) 1.1 BRCA -mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer TAL…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 217439
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Talzennatalazoparib | Talazoparib tosylate 1 mg/1 | Capsule, Liquid filledOral | U.S. Pharmaceuticals | 63539-031 |
| Talzennatalazoparib | Talazoparib tosylate .5 mg/1 | Capsule, Liquid filledOral | U.S. Pharmaceuticals | 63539-025 |
| Talzennatalazoparib | Talazoparib tosylate .1 mg/1 | Capsule, Liquid filledOral | Pfizer Laboratories Div Pfizer Inc | 0069-0252 |
| Talzennatalazoparib | Talazoparib tosylate .5 mg/1 | Capsule, Liquid filledOral | Pfizer Laboratories Div Pfizer Inc | 0069-0546 |
| Talzennatalazoparib | Talazoparib tosylate .25 mg/1 | Capsule, Liquid filledOral | Pfizer Laboratories Div Pfizer Inc | 0069-0353 |
| Talzennatalazoparib | Talazoparib tosylate 1 mg/1 | Capsule, Liquid filledOral | Pfizer Laboratories Div Pfizer Inc | 0069-0757 |
| Talzennatalazoparib | Talazoparib tosylate .35 mg/1 | Capsule, Liquid filledOral | Pfizer Laboratories Div Pfizer Inc | 0069-0454 |